Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVT078 in relapsed/refractory multiple myeloma
NCT04123418Phase 1Terminated
- Sponsor
- Novartis
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of WVT078 in multiple myeloma (MM) (2 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicity at 28 days, Frequency of Dose Interruptions and 3 more. Started Dec 2019; status: terminated.
02
Drugs
WVT078
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04123418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123418.